logo

Clementia Pharmaceuticals Inc. (CMTA)



Trade CMTA now with
  Date
  Headline
8/16/2018 6:31:57 AM Clementia Reports Completion Of Enrollment In Phase 3 MOVE Trial For FOP
8/10/2018 7:48:01 AM Wedbush Is Increasing Clementia Pharmaceuticals Inc. (CMTA) FY18 Estimate To -1.52 From -1.89
8/10/2018 7:47:43 AM Wedbush Is Raising Clementia Pharmaceuticals Inc. (CMTA) Q4 18 Estimate To -0.40 From -0.52
8/10/2018 7:47:30 AM Wedbush Is Raising Clementia Pharmaceuticals Inc. (CMTA) Q3 18 Estimate To -0.38 From -0.49
8/10/2018 7:47:05 AM Wedbush Reiterates Clementia Pharmaceuticals Inc. (CMTA) At Outperform With $26 Price Target
8/9/2018 6:41:01 AM Clementia Pharma Q2 Net Loss $10.8 Mln Or $0.34/Shr Vs Loss $23.3 Mln Or $9.54/Shr Last Year
7/13/2018 6:31:06 AM Clementia Pharma Appoints Steve Forte As CFO, Effective August 3
7/5/2018 6:35:32 AM Clementia Pharma Appoints Industry Executive Shawn Tomasello To Its Board Of Directors
5/24/2018 10:36:58 AM Prevail Therapeutics Appoints Francois Nader To Its Board
5/23/2018 6:33:07 AM Clementia Reports Positive Phase 2 Part B Data Showing Treatment With Palovarotene
5/10/2018 8:19:55 AM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) FY18 Estimate To -1.89 From -1.57
5/10/2018 8:19:38 AM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q4 18 Estimate To -0.52 From -0.43
5/10/2018 8:19:19 AM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q3 18 Estimate To -0.49 From -0.41
5/10/2018 8:19:06 AM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) Q2 18 Estimate To -0.46 From -0.38
5/9/2018 6:39:33 AM Clementia Pharma Q1 Net Loss $13.2 Mln Or $0.42/Shr Vs Loss $41.3 Mln Or $17.48/Shr Last Year
4/20/2018 6:32:20 AM Clementia Initiates Phase 2 MO-Ped Trial For Palovarotene In Patients With Multiple Osteochondromas